Curcumin,a potent anti-tumor reagent,is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation

被引:0
|
作者
Hong-li LIU~2
机构
基金
中国国家自然科学基金;
关键词
curcumin; histone deacetylase; acetylated histone H4; Raji;
D O I
暂无
中图分类号
R733.1 [网状内皮系统肿瘤];
学科分类号
100214 ;
摘要
Aim:To investigate curcumin(diferuloylmethane)induced apoptosis and its mo-lecular mechanism of action in B-NHL cell line Raji cells.Methods:Raji cells werecultured in RPMI-1640 medium and treated with curcumin in different concentra-tions.3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium(MTT)assay wasused to detect growth inhibition and Hoechst 33258 staining was used to detectapoptosis.Immunocytochemistry and Western blot were used to detect the ex-pressions of histone deacetylase 1,3,and 8(HDAC 1,HDAC3,and HDACS)andacetylated histone H4(Ac-histone H4)protein.Results:Curcumin inhibited theproliferation of B-NHL cell line Raji cells with a 36-h IC50value of 24.1±2.0μmol/L.Hoechst 33258 staining showed that curcumin could induce Raji cell apoptosis.The expression levels of HDAC1,HDAC3,and HDAC8 proteins were downregulat-ed following curcumin treatment in Raji cells,whereas Ac-histone H4 protein expres-sion was upregulated after treatment with curcumin.Conclusion:Curcumin,as anew member of the histone deacetylase inhibitors,can inhibit the expression ofclass I HDACs(HDAC1,HDAC3,and HDAC8),and can increase the expressionof Ac-histone H4 in Raji cells.Curcumin plays an important role in regulatingB-NHL cell line Raji cell proliferation and apoptosis.
引用
收藏
页码:603 / 609
页数:7
相关论文
共 50 条
  • [41] Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo
    Huang, Han-Li
    Peng, Chieh-Yu
    Lai, Mei-Jung
    Chen, Chun-Han
    Lee, Hsueh-Yun
    Wang, Jing-Chi
    Liou, Jing-Ping
    Pan, Shiow-Lin
    Teng, Che-Ming
    ONCOTARGET, 2015, 6 (07) : 4976 - 4991
  • [42] A Novel CD20xCD3 Bispecific Fully Human Antibody Induces Potent Anti-Tumor Effects Against B Cell Lymphoma in Mice
    Varghese, Bindu
    Menon, Jayanthi
    Rodriguez, Luis
    Haber, Lauric
    Olson, Kara
    Duramad, Paurene
    Oyejide, Adelekan
    Smith, Eric
    Thurston, Gavin
    Kirshner, Jessica
    BLOOD, 2014, 124 (21)
  • [43] INDUCTION OF CASPASE-DEPENDENT APOPTOSIS AND DOWN-REGULATION OF NF-κB AND AKT SIGNALING IS INVOLVED IN THE SYNERGISTIC ANTI-TUMOR EFFECT OF GEMCITABINE AND HISTONE DEACETYLASE INHIBITOR, TRICHOSTATIN A IN HUMAN BLADDER CANCER CELLS
    Yoon, C. Y.
    Jeon, H. G.
    Lee, J. S.
    Kim, B. S.
    Oh, J. J.
    Jung, C. W.
    Jeong, S. J.
    Hong, S. K.
    Byun, S. S.
    Lee, S. E.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 166 - 166
  • [44] Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma
    Ding, Ning
    Li, Xitao
    Shi, Yunfei
    Ping, Lingyan
    Wu, Lina
    Fu, Kai
    Feng, Lixia
    Zheng, Xiaohui
    Song, Yuqin
    Pan, Zhengying
    Zhu, Jun
    ONCOTARGET, 2015, 6 (17) : 15122 - 15136
  • [45] Identification of compound CA-5f as a novel late-stage autophagy inhibitor with potent anti-tumor effect against non-small cell lung cancer
    Zhang, Lu
    Qiang, PengFei
    Yu, JingTing
    Miao, YiMing
    Chen, ZhiQiang
    Qu, Ju
    Zhao, QianBing
    Chen, Zhuo
    Liu, Yachao
    Yao, Xin
    Liu, Bin
    Cui, LiuQing
    Jing, HongJuan
    Sun, Gangchun
    AUTOPHAGY, 2019, 15 (03) : 391 - 406
  • [46] Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma
    Ma, Jiao
    Xing, Wei
    Coffey, Greg
    Dresser, Karen
    Lu, Kellie
    Guo, Ailin
    Raca, Gordana
    Pandey, Anjali
    Conley, Pamela
    Yu, Hongbo
    Wang, Y. Lynn
    ONCOTARGET, 2015, 6 (41) : 43881 - 43896
  • [47] DS-7300a, a novel B7-H3-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, exhibits potent anti-tumor effects in nonclinical models
    Yamato, M.
    Hasegawa, J.
    Hattori, C.
    Maejima, T.
    Shibutani, T.
    Deguchi, T.
    Izumi, N.
    Watanabe, A.
    Nishiya, Y.
    Nakada, T.
    Abe, Y.
    Agatsuma, T.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S14 - S15
  • [48] MLN2238, a Novel and Potent Proteasome Inhibitor, Induces Caspase-Dependent Cell Death, Cell-Cycle Arrest, and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Chemotherapy Sensitive or Resistant B-Cell Lymphoma Cell Lines
    Gu, Juan
    Ritesh, Patil
    Mavis, Cory
    Deeb, George
    Gibbs, John
    Hernandez-Ilizaliturri, Francisco J.
    Czuczman, Myron S.
    BLOOD, 2010, 116 (21) : 1606 - 1606
  • [49] Amdizalisib (HMPL-689), a highly selective PI3Kd inhibitor, exhibits potent anti-tumor activity in pre-clinical B-cell lymphoma models
    Hu, Jia
    Wang, Jianhan
    Dai, Xiaoming
    He, Jianlin
    Liang, Junqing
    Yu, Ying
    Yu, Juntao
    Yang, Na
    Wang, Linfang
    Cai, Yu
    Li, Xiong
    Qing, Weiguo
    Ren, Yongxin
    Su, Weiguo
    CANCER RESEARCH, 2022, 82 (12)
  • [50] High Frequency of CD74 Expression in B-Cell Non-Hodgkin's Lymphoma (NHL) and Targeting with STRO-001, a Novel Anti-CD74 Antibody Drug Conjugate (ADC) with Potent I n Vitro Cytotoxicty and In Vivo Anti-Tumor Activity
    Yu, Abigail
    Abrahams, Cristina
    Embry, Millicent
    Li, Xiaofan
    Zhao, Shuchun
    Henningsen, Robert
    DeAlmeida, Venita
    Matheny, Shannon
    Kline, Toni
    Yam, Alice
    Stafford, Ryan
    Natkunam, Yasodha
    Hallam, Trevor
    Lupher, Mark
    Molina, Arturo
    BLOOD, 2017, 130